ArticlePloS one2025
Carbapenem-resistant Enterobacterales among patients with bloodstream infections in South Africa: Consolidated surveillance data, 2015-2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Carbapenem-resistant Enterobacterales infection at a South African paediatric hospital.BMC infectious diseases · 2026Article
- Fosfomycin Use in Treating Severe Difficult-to-Treat Gram-Negative Infections-A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2026Review
- Epidemiology of ESBL-Producing, Carbapenem-Resistant, and Carbapenemase-Producing Enterobacterales in Southern Africa.Antibiotics (Basel, Switzerland) · 2026Review
- Bacterial and fungal pathogens causing neonatal sepsis and associated antimicrobial resistance in South African neonatal units-a systematic review.JAC-antimicrobial resistance · 2025Review
- Characterization of Carbapenem-Resistant Gram-Negative Bacilli Isolates in Multispecialty Private Hospitals in Lagos, Nigeria.Infectious disease reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA fifth of blood cultures from patients with infections acquired in a healthcare setting in South Africa will yield an organism. Carbapenem-resistant Enterobacterales (CREs), specifically Klebsiella pneumoniae are the most predominant Gram-negative bacteria (GNB) isolated among bloodstream infections (BSI). Additionally, the multidrug-resistant nature of these organisms is not only a threat to patients but it also poses a big public health challenge to current treatments and highlights the need for the development of new antimicrobials. Therefore, CRE have been placed on the critical priority list by the World Health Organization (WHO). We aimed to provide a holistic overview of the GERMS-SA CRE BSI surveillance data from 01 July 2015-31 December 2021.
methodsWe conducted a cross-sectional study. CRE BSI was defined as the isolation of Enterobacterales resistant to any carbapenem (imipenem, ertapenem, meropenem and doripenem). All culture-confirmed cases captured on the database from 01 July 2015-31 December 2021 were considered for descriptive analysis and all cases with additional clinical information from 01 July 2015-31 December 2020 collected through the case report form (CRF) were used to perform analytical inferential statistics. We calculated the case fatality ratio of all cases with the outcome reported.
resultsOf the 5,258 culture-confirmed cases in the database for the surveillance period, the median age was 31 years (interquartile range 11-50) and 53.0% (2,787/5,258) were males. The majority of cases (64.6%, 1,361/2,017) were from Gauteng province that are participating in GERMS-SA surveillance. Of the cultures that isolated organisms, 53.0% (2,699/5,258) were sent to a reference laboratory for further testing. Case report forms were collected from 2,935 cases and these included audit cases. The clinical outcome was recorded for 99.5% (2,919/2,935) of the cases with a case fatality ratio of 36.1% (1,055/2,919). About 44.5% (1,298/2,916) of the cases had pre-existing conditions, most of which were other (n = 601). Most cases (78.4%, 2,288/2,920) received antibiotics on the current admission and 85.4% (2,488/2,912) had devices inserted. Of the 2,699 viable isolates, 2,100 (78%) were confirmed to be resistant to any of the carbapenems and 93.0% (n = 1,951) were carbapenemase-producing CREs. The carbapenem-resistant rate of all BSI was 1.9% (5,258/270,239). Of the CRE isolates, most were highly susceptible to fosfomycin (80.4%, 1,688/2,100). The potential significant risk factors for CRE BSI related mortality from multivariable logistic regression were being male, over 60 years, with pre-existing conditions, previously on antibiotics, mechanical ventilation as well as oxygenation, and previous hospital admission.
conclusionPeriodic surveillance for CRE should be performed on regular basis to support infection prevention and stewardship program at each facility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.